Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009
Michaela A. Dinan1,2,3, Xiaojuan Mi4, Shelby D. Reed1,2,3, Bradford R. Hirsch1,2,3, Gary H. Lyman5,6, Lesley H. Curtis1,7
1Department of Medicine, Duke University School of Medicine, Durham, North Carolina
2Duke Cancer Institute, Duke University School of Medicine, Durham, North Carolina
3Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina2Duke Cancer Institute, Duke University School of Medicine, Durham, North Carolina3Department of Medicine, Duke University School of Medicine, Durham, North Caroli
4Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
5Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle
6Hutchinson Institute for Cancer Outcomes Research, Public Health Sciences Division and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington5Division of Medical Oncology, Department of Medicine, University of Washington S
7Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina3Department of Medicine, Duke University School of Medicine, Durham, North Carolina